Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicenter cohort study.

Tomohisa UchidaNaoki IwamotoShoichi FukuiShimpei MorimotoToshiyuki AramakiFumiko ShomuraKoichiro AratakeKatsumi EguchiYukitaka UekiAtsushi Kawakami

Published in: Rheumatology (Oxford, England) (2023)

The infectious disease IR in RA was comparable between tofacitinib and baricitinib, but the HZ rate was high compared with TNF inhibitors. The malignancy rate in JAK-inhibitor treatment was high but not significantly different from those of a general population and TNF-inhibitor users.

Keyphrases

risk assessment
rheumatoid arthritis
infectious diseases
disease activity
combination therapy
clinical trial
systemic lupus erythematosus
systemic sclerosis